Annovis Bio
ANVS
44 hedge funds and large institutions have $3.13M invested in Annovis Bio in 2025 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 16 increasing their positions, 4 reducing their positions, and 8 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 4
63% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 8
10% more funds holding
Funds holding: 40 → 44 (+4)
0.71% less ownership
Funds ownership: 11.42% → 10.71% (-0.71%)
61% less capital invested
Capital invested by funds: $7.93M → $3.13M (-$4.8M)
65% less call options, than puts
Call options by funds: $132K | Put options by funds: $381K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$556K |
| 2 |
Two Sigma Investments
New York
|
+$475K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$343K |
| 4 |
Two Sigma Advisers
New York
|
+$284K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$222K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$659K |
| 2 |
Jane Street
New York
|
-$343K |
| 3 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$258K |
| 4 |
AWS
Atria Wealth Solutions
New York
|
-$65.4K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$58.6K |
ANVS Hedge Fund Activity: Q1 2025 in Review
44 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Annovis Bio (ANVS) for Q1 2025, worth a combined $3.13M — down 61% from $7.93M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new ANVS positions and 8 closed out — a net gain of 5 holders — while 16 added to existing stakes and 4 trimmed.
The largest buyer was Vanguard Group, adding an estimated $556K. The largest seller was Citadel Advisors, exiting entirely with an estimated $659K sold.
- 44 institutional investors held Annovis Bio (ANVS) as of Q1 2025, up from 40 in Q4 2024.
- Funds reported $3.13M of Annovis Bio stock for Q1 2025, down 61% quarter-over-quarter.
- 13 funds opened new Annovis Bio positions in Q1 2025 and 8 closed out, a net change of +5 holders.
- The largest Annovis Bio buyer in Q1 2025 was Vanguard Group, an estimated $556K added.
- The largest Annovis Bio seller in Q1 2025 was Citadel Advisors, an estimated $659K sold.
Based on aggregated 13F filings for Q1 2025.